Raf kinase inhibitor protein: A prostate cancer metastasis suppressor gene

Cancer Letters

Volumn 207, Issue 2, 2004, Pages 131-137

  Keller, Evan T ^a   Fu, Zheng ^a   Yeung, Kam ^b   Brennan, Meghan ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Apoptosis; Metastasis; Phosphatidyl ethanolamine binding protein; Prostate carcinoma; Signal transduction

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 8; CASPASE 9; FAS ANTIGEN; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE 2; GUANINE NUCLEOTIDE BINDING PROTEIN; INHIBITOR PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MORPHINE; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE C; PROTEIN P53; PROTEIN P63; PROTEIN P73; RAF PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER GROWTH; CELL SURVIVAL; DOWN REGULATION; ENZYME PHOSPHORYLATION; GENE FUNCTION; GENE IDENTIFICATION; GENE SILENCING; HUMAN; MALE FERTILITY; METASTASIS; MOLECULAR MECHANICS; MOLECULAR MODEL; NONHUMAN; NUCLEOTIDE BINDING SITE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SPERMATOGENESIS; SUPPRESSOR GENE; TISSUE DISTRIBUTION; UPREGULATION;

EID: 1842557438     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2004.02.006     Document Type: Review

References (48)

1. Simister P.C., Banfield M.J., Brady R.L. The crystal structure of PEBP-2, a homologue of the PEBP/RKIP family. Acta Crystallogr. D Biol. Crystallogr. 58:2002;1077-1080.
2. Vallee B.S., Tauc P., Brochon J.C., Maget-Dana R., Lelievre D., Metz-Boutigue M.H., et al. Behaviour of bovine phosphatidylethanolamine-binding protein with model membranes. Evidence of affinity for negatively charged membranes. Eur. J. Biochem. 268:2001;5831-5841.
3. Yeung K., Seitz T., Li S., Janosch P., McFerran B., Kaiser C., et al. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature. 401:1999;173-177.
4. Banfield M.J., Barker J.J., Perry A.C., Brady R.L. Function from structure? The crystal structure of human phosphatidylethanolamine-binding protein suggests a role in membrane signal transduction. Structure. 6:1998;1245-1254.
5. Corbit K.C., Trakul N., Eves E.M., Diaz B., Marshall M., Rosner M.R. Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein. J. Biol. Chem. 2003;M210015200.
6. Maki M., Matsukawa N., Yuasa H., Otsuka Y., Yamamoto T., Akatsu H., et al. Decreased expression of hippocampal cholinergic neurostimulating peptide precursor protein mRNA in the hippocampus in Alzheimer disease. J. Neuropathol. Exp. Neurol. 61:2002;176-185.
7. Mitake S., Ojika K., Katada E., Otsuka Y., Matsukawa N., Fujimori O. Accumulation of hippocampal cholinergic neurostimulating peptide (HCNP)-related components in Hirano bodies. Neuropathol. Appl. Neurobiol. 21:1995;35-40.
8. Mitake S., Katada E., Otsuka Y., Matsukawa N., Iwase T., Tsugu T., et al. Possible implication of hippocampal cholinergic neurostimulating peptide (HCNP)-related components in Hirano body formation. Neuropathol. Appl. Neurobiol. 22:1996;440-445.
9. Tsugu Y., Ojika K., Matsukawa N., Iwase T., Otsuka Y., Katada E., Mitake S. High levels of hippocampal cholinergic neurostimulating peptide (HCNP) in the CSF of some patients with Alzheimer's disease. Eur. J. Neurol. 5:1998;561-569.
10. Schoentgen F., Jolles P. From structure to function: possible biological roles of a new widespread protein family binding hydrophobic ligands and displaying a nucleotide binding site. Fed. Eur. Biochem. Soc. Lett. 369:1995;22-26.
11. Frayne J., McMillen A., Love S., Hall L. Expression of phosphatidylethanolamine-binding protein in the male reproductive tract: immunolocalisation and expression in prepubertal and adult rat testes and epididymides. Mol. Reprod. Dev. 49:1998;454-460.
12. Fu Z., Smith P.C., Zhang L., Rubin M.A., Dunn R.L., Yao Z., Keller E.T. Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J. Natl Cancer Inst. 95:2003;878-889.
13. Jones R., Hall L. A 23 kDa protein from rat sperm plasma membranes shows sequence similarity and phospholipid binding properties to a bovine brain cytosolic protein. Biochim. Biophys. Acta. 1080:1991;78-82.
14. Perry A.C., Hall L., Bell A.E., Jones R. Sequence analysis of a mammalian phospholipid-binding protein from testis and epididymis and its distribution between spermatozoa and extracellular secretions. Biochem. J. 301:(Pt 1):1994;235-242.
15. Saunders P.T., McKinnell C., Millar M.R., Gaughan J., Turner K.J., Jegou B., et al. Phosphatidylethanolamine binding protein is an abundant secretory product of haploid testicular germ cells in the rat. Mol. Cell. Endocrinol. 107:1995;221-230.
16. Frayne J., Ingram C., Love S., Hall L. Localisation of phosphatidylethanolamine-binding protein in the brain and other tissues of the rat. Cell Tissue Res. 298:1999;415-423.
17. Katada E., Mitake S., Matsukawa N., Otsuka Y., Tsugu Y., Fujimori O., Ojika K. Distribution of hippocampal cholinergic neurostimulating peptide (HCNP)-like immunoreactivity in organs and tissues of young Wistar rats. Histochem. Cell Biol. 105:1996;43-51.
18. Katada E., Ojika K., Mitake S., Ueda R. Neuronal distribution and subcellular localization of HCNP-like immunoreactivity in rat small intestine. J. Neurocytol. 29:2000;199-207.
19. Moore C., Perry A.C., Love S., Hall L. Sequence analysis and immunolocalisation of phosphatidylethanolamine binding protein (PBP) in human brain tissue. Brain Res. Mol. Brain Res. 37:1996;74-78.
20. Taiji M., Tohdoh N., Ojika K. Neuronal expression of hippocampal cholinergic neurostimulating peptide (HCNP)-precursor mRNA in rat brain. J. Neurosci. Res. 45:1996;202-215.
21. Tohdoh N., Tojo S., Kimura M., Ishii T., Ojika K. Mechanism of expression of the rat HCNP precursor protein gene. Brain Res. Mol. Brain Res. 45:1997;24-32.
22. Ojika K., Katada E., Tohdoh N., Mitake S., Otsuka Y., Matsukawa N., Tsugu Y. Demonstration of deacetylated hippocampal cholinergic neurostimulating peptide and its precursor protein in rat tissues. Brain Res. 701:1995;19-27.
23. Bucquoy S., Jolles P., Schoentgen F. Relationships between molecular interactions (nucleotides, lipids and proteins) and structural features of the bovine brain 21-kDa protein. Eur. J. Biochem. 225:1994;1203-1210.
24. Grandy D.K., Hanneman E., Bunzow J., Shih M., Machida C.A., Bidlack J.M., Civelli O. Purification, cloning, and tissue distribution of a 23-kDa rat protein isolated by morphine affinity chromatography. Mol. Endocrinol. 4:1990;1370-1376.
25. Robinson L.C., Tatchell K. TFS1: a suppressor of cdc25 mutations in Saccharomyces cerevisiae. Mol. Gen. Genet. 230:1991;241-250.
26. Schoentgen F., Seddiqi N., Bucquoy S., Jolles P., Lemesle-Varloot L., Provost K., Mornon J.P. Main structural and functional features of the basic cytosolic bovine 21 kDa protein delineated through hydrophobic cluster analysis and molecular modelling. Protein Engng. 5:1992;295-303.
27. Kroslak T., Koch T., Kahl E., Hollt V. Human phosphatidylethanolamine- binding protein facilitates heterotrimeric G protein-dependent signaling. J. Biol. Chem. 276:2001;39772-39778.
28. Yeung K., Janosch P., McFerran B., Rose D.W., Mischak H., Sedivy J.M., Kolch W. Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol. Cell Biol. 20:2000;3079-3085.
29. Bazzi M.D., Youakim M.A., Nelsestuen G.L. Importance of phosphatidylethanolamine for association of protein kinase C and other cytoplasmic proteins with membranes. Biochemistry. 31:1992;1125-1134.
30. Lorenz K., Lohse M.J., Quitterer U. Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature. 426:2003;574-579.
31. Kaufmann S.H., Hengartner M.O. Programmed cell death: alive and well in the new millennium. Trends Cell Biol. 11:2001;526-534.
32. Budihardjo I., Oliver H., Lutter M., Luo X., Wang X. Biochemical pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev. Biol. 15:1999;269-290.
33. Newton K., Strasser A. Cell death control in lymphocytes. Adv. Immunol. 76:2000;179-226.
34. Green D., Kroemer G. The central executioners of apoptosis: caspases or mitochondria? Trends Cell Biol. 8:1998;267-271.
35. Thornberry N.A., Lazebnik Y. Caspases: enemies within. Science. 281:1998;1312-1316.
36. Kleeff J., Kornmann M., Sawhney H., Korc M. Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells. Int. J. Cancer. 86:2000;399-407.
37. Kuwabara M., Takahashi K., Inanami O. Induction of apoptosis through the activation of SAPK/JNK followed by the expression of death receptor Fas in X-irradiated cells. J. Radiat. Res. (Tokyo). 44:2003;203-209.
38. Sordet O., Khan Q.A., Kohn K.W., Pommier Y. Apoptosis induced by topoisomerase inhibitors. Curr. Med. Chem. Anti-Canc. Agents. 3:2003;271-290.
39. Truong T., Sun G., Doorly M., Wang J.Y., Schwartz M.A. Modulation of DNA damage-induced apoptosis by cell adhesion is independently mediated by p53 and c-Abl. Proc. Natl Acad. Sci. USA. 100:2003;10281-10286.
40. Marabese M., Vikhanskaya F., Rainelli C., Sakai T., Broggini M. DNA damage induces transcriptional activation of p73 by removing C-EBPalpha repression on E2F1. Nucleic Acids Res. 31:2003;6624-6632.
41. Cory S., Huang D.C., Adams J.M. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene. 22:2003;8590-8607.
42. Yeung K.C., Rose D.W., Dhillon A.S., Yaros D., Gustafsson M., Chatterjee D., et al. Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol. Cell Biol. 21:2001;7207-7217.
43. Welch D.R., Rinker-Schaeffer C.W. What defines a useful marker of metastasis in human cancer? J. Natl Cancer Inst. 91:1999;1351-1353.
44. Yoshida B.A., Sokoloff M.M., Welch D.R., Rinker-Schaeffer C.W. Metastasis-suppressor genes: a review and perspective on an emerging field. J. Natl Cancer Inst. 92:2000;1717-1730.
45. Dong J.T., Suzuki H., Pin S.S., Bova G.S., Schalken J.A., Isaacs W.B., et al. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res. 56:1996;4387-4390.
46. Yang X., Welch D.R., Phillips K.K., Weissman B.E., Wei L.L. KAI1, a putative marker for metastatic potential in human breast cancer. Cancer Lett. 119:1997;149-155.
47. Steeg P.S., Bevilacqua G., Kopper L., Thorgeirsson U.P., Talmadge J.E., Liotta L.A., Sobel M.E. Evidence for a novel gene associated with low tumor metastatic potential. J. Natl Cancer Inst. 80:1988;200-204.
48. Fu Z., Dozmorov I., Keller E. Osteoblasts produce soluble factors that induce a gene expression pattern in non-metastatic prostate cancer cells, similar to that found in bone metastatic prostate cancer cells. Prostate. 51:2002;10-20.